Gregg W. Stone, MD, FACC, FSCAI

Feature

Taxus: Where Are We Now?Talking with Gregg Stone, MD

06/19/2008

What questions still remain open about the Taxus stent? We certainly need long-term follow up, to make sure that the device is safe and effective over extended periods of time. From favorable long-term results of animal studies we expect...

What questions still remain open...

06/19/2008

Cath Lab Digest

Original Contribution

Outcomes of Vascular Closure Device Use After Transfemoral Coronary Intervention: Insights From the EXCEL Trial

08/01/2021

Paul Guedeney , MD;

Joseph F. Sabik III, MD;

Charles A. Simonton III, MD;

Zixuan Zhang , MS;

Ovidiu Dressler , MD;

Arie Pieter Kappetein , MD, PhD;

Gregg W. Stone , MD, FACC, FSCAI;

Patrick W. Serruys , MD, PhD;

David E. Kandzari , MD;

Marie-Claude Morice , MD, FESC, FACC;

Roxana Mehran , MD;

Toshiki Kuno , MD, PhD;

Ori Ben-Yehuda , MD;

Bimmer E.P.M. Claessen , MD, PhD;

The study objective is to assess the safety and efficacy of using vascular closure devices in percutaneous coronary intervention for left main coronary artery disease.

The study objective is to assess...

08/01/2021

Journal of Invasive Cardiology

Calcium Corner

Stenting the Unprotected Left Main: Finding Answers With the EXCEL Trial

10/28/2011

Gregg W. Stone , MD, FACC, FSCAI;

EXCEL is a global, prospective, multi-center, randomized trial to assess the safety and efficacy of the Xience Prime/Xience V everolimus-eluting stent (Abbott Vascular, Santa Clara, California) compared to coronary artery bypass grafting...

EXCEL is a global, prospective,...

10/28/2011

Cath Lab Digest

Acute Angiographic and Clinical Results of the NIR w/SOX Stent

08/01/2008

Roxana Mehran , MD;

Jeffrey W. Moses , MD;

Michael B. Collins , MD;

Edward M. Kreps , MD;

Milena Adamian , MD;

Issam Moussa , MD;

Yoshio Kobayashi , MD;

Kartik Desai , MD;

Gregg W. Stone , MD, FACC, FSCAI;

Martin B. Leon , MD;

George D. Dangas , MD, PhD;

Lower restenosis rates were shown in selected lesions with the first-generation Palmaz-Schatz stent when compared to conventional balloon angioplasty.1 However, because the Palmaz-Schatz stent and its delivery system were rigid, stent...

Lower restenosis rates were...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Impact of Chronic Total Occlusions on Revascularization Scores and Outcome Prediction

03/15/2017

Dimitrios Karmpaliotis , MD, PhD;

Roxana Mehran , MD;

Ajay J. Kirtane , MD, SM;

Bjorn Redfors , MD, PhD;

Philippe Généreux , MD;

Girma Minalu Ayele , PhD;

Dominic P. Francese , MPH;

Adriano Caixeta , MD, PhD;

Emmanouil S. Brilakis , MD, PhD, FACC, FAHA, FESC, FSCAI;

Gregg W. Stone , MD, FACC, FSCAI;

This study evaluates the contribution of chronic total occlusion (CTO)-related SYNTAX score (SS) to the overall SS for patients with CTO and compares the traditional SS to a simplified variant.

This study evaluates the...

03/15/2017

Journal of Invasive Cardiology

Feature

TAXUS Clinical Trials: TCT Recap

06/19/2008

Gregg W. Stone , MD, FACC, FSCAI;

Dr. Stone, at the recent TCT Conference, findings were presented on a variety of TAXUS Clinical Trials. What trials did you report on, and what were some of the overall findings? At TCT my colleagues and I delivered extensive long-term TAXUS...

Dr. Stone, at the recent TCT...

06/19/2008

Cath Lab Digest

Technology Pulse

Anticipating the Era of Drug-Eluting Stents

06/19/2008

Gregg W. Stone , MD, FACC, FSCAI;

Components of a Drug-Eluting Stent Program Four key elements that must be considered when developing a drug-eluting stent include: The drug, The polymer, Release kinetics, and The stent delivery system. The Drug Restenosis...

Components of a Drug-Eluting...

06/19/2008

Cath Lab Digest

Hurry, It’s a STEMI! But How Quick is Too Quick for Safety?

07/31/2013

David R. Holmes Jr., MD;

E. Magnus Ohman , MD;

Barry F. Uretsky , MD;

Peter B. Berger , MD;

Eric Bates ;

Gregg W. Stone , MD, FACC, FSCAI;

Robert J. Applegate , MD;

Sunil V. Rao , MD, FACC, FSCAI;

Ted Feldman , MD, FSCAI, FACC, FESC;

Morton J. Kern , MD, MSCAI, FACC, FAHA;

Christopher J. White , DO, MD;

I asked my expert cath lab colleagues to weigh in on this issue with 3 quick answers on whether forced reduction of D2B time is 1) beneficial for the patient or 2) the hospital or 3) the interventionalist, and if you have time, a short...

I asked my expert cath lab...

07/31/2013

Cath Lab Digest

Clinical Images

Imaging and Physiology to Guide Venous Graft Interventions Without Contrast Administration in Advanced Renal Failure

10/23/2017

Gregg W. Stone , MD, FACC, FSCAI;

Gary S. Mintz , MD;

Ziad A. Ali , MD, DPhil;

Yasir Parviz , MBBS, MRCP;

Khady Fall , MD;

Akiko Maehara , MD;

Ori Ben-Yehuda , MD;

We describe step-by-step “zero-contrast” saphenous vein bypass graft intervention using a modified technique.

We describe step-by-step...

10/23/2017

Journal of Invasive Cardiology

Feature

SPIRIT III: Comparison of the Xience V Everolimus-Eluting Coronary Stent System with the Taxus Paclitaxel-Eluting Coronary Stent

06/19/2008

Gregg W. Stone , MD, FACC, FSCAI;

The purpose of the Xience V stent was to try and put together a best-in-class drug, enhanced durable polymer and optimized metallic stent backbone. The drug that was used was everolimus, very similar to sirolimus, which is known to have very...

The purpose of the Xience V...

06/19/2008

Cath Lab Digest